PeRSEVERE project looks at withdrawal of consent in clinical studies

07 April 2022

PRincipleS for handling end-of-participation EVEnts in clinical trials REsearch (PeRSEVERE)

The UKCRC Registered CTU Network’s PeRSEVERE project has developed principles to guide the preparation for and management of early end-of-participation in clinical trials and other research studies.

Laura Clifton-Hadley, Trials Group Lead for haematology and brain trials at the CTC, has been acting as a member of the steering group, which describes its work as follows:

Background

The right of research participants to withdraw informed consent and stop taking part in some or all of the research activities is a well-established, fundamental part of ethical clinical research. The PeRSEVERE project is about the practical implications of this right. The question at the heart of the project is: how should we design and carry out clinical trials and other research, given that we know some participants will stop participating early? In our project, we have considered things such as how research studies are designed, what information is given to trial participants about stopping participation early, and what exactly should happen when a participant says they want to stop or reduce their participation.

Outputs

The final PeRSEVERE principles, with explanatory guidance, can be found here. We encourage everyone involved in designing, running, funding or overseeing clinical trials to review our suggestions and consider how they could be put into practice. The PeRSEVERE collaboration intends to release more detailed guidance in due course regarding how the principles can be implemented.

More details on the PeRSEVERE project, including the list of the principles mentioned above, can be found here.

More news articles

(Publication) Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial

Ujjal Mallick, Kate Newbold, Matthew Beasley, Kate Garcez, Jonathan Wadsley, Sarah J Johnson, Tim Stephenson, Mark Gaze, Andrew Goodman, Sar [...]

Trials community celebrates International Clinical Trials Day

Today marks International Clinical Trials Day, a global ACRP initiative intended to educate and inform the wider public about work being don [...]

(Publication) Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial

Michael Northend, William Wilson, Kushani Ediriwickrema, Laura Clifton-Hadley, Wendi Qian, Zaynab Rana, Tanya-Louise Martin, William Townsen [...]

(Publication) High-Dose Methotrexate in Children and Young Adults With ALL and Lymphoblastic Lymphoma: Results of the Randomized Phase III Study UKALL 2011

Kirkwood AA, Goulden N, Moppett J, Samarasinghe S, Hough R, Rowntree C, Lawson S, Kearns P, Lawson A, Vora A.

Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map

Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899

CTC staff

University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000